STATE-OF-THE-ART PAPER
Natriuretic Peptides
Lori B. Daniels, MD* and
Alan S. Maisel, MD, FACC
Division of Cardiology, University of California at San Diego, and the Division of Cardiology, Veteran’s Affairs San Diego Healthcare System, San Diego, California.
Manuscript received July 31, 2007;
revised manuscript received September 10, 2007,
accepted September 26, 2007.
* Reprint requests and correspondence: Dr. Lori B. Daniels, Division of Cardiology, University of California, San Diego, MC 0986, 9350 Campus Point Drive, Suite 1D, La Jolla, California 92037-1300. (Email: loridaniels{at}ucsd.edu).
Natriuretic peptides (NPs) are released from the heart in response to pressure and volume overload. B-type natriuretic peptide (BNP) and N-terminal-proBNP have become important diagnostic tools for assessing patients who present acutely with dyspnea. The NP level reflects a compilation of systolic and diastolic function as well as right ventricular and valvular function. Studies suggest that using NPs in the emergency department can reduce the consumption of hospital resources and can lower costs by either eliminating the need for other, more expensive tests or by establishing an alternative diagnosis that does not require hospital stay. Caveats such as body mass index and renal function must be taken into account when analyzing NP levels. Natriuretic peptide levels have important prognostic value in multiple clinical settings, including in patients with stable coronary artery disease and with acute coronary syndromes. In patients with decompensated heart failure due to volume overload, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels. Knowing a patient’s NP levels might thus assist with hemodynamic assessment and subsequent treatment titration. Monitoring NP levels in the outpatient setting might also improve patient care and outcomes.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | ANP = atrial natriuretic peptide | | AUC = area under the receiver-operating characteristic curve | | BNP = B-type natriuretic peptide | | CAD = coronary artery disease | | CHF = congestive heart failure | | ED = emergency department | | GFR = glomerular filtration rate | | HF = heart failure | | LV = left ventricle/ventricular | | MI = myocardial infarction | | NP = natriuretic peptide | | NPR = natriuretic peptide receptor | | NTproBNP = amino-terminal fragment of B-type natriuretic peptide | | NYHA = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
A. Cohen-Solal, D. Logeart, B. Huang, D. Cai, M. S. Nieminen, and A. Mebazaa
Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure
J. Am. Coll. Cardiol.,
June 23, 2009;
53(25):
2343 - 2348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gheorghiade and P. S. Pang
Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?
J. Am. Coll. Cardiol.,
June 23, 2009;
53(25):
2349 - 2352.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Chugh and K. Reinier
Predicting Sudden Death in the General Population: Another Step, N Terminal B-Type Natriuretic Factor Levels
Circulation,
June 9, 2009;
119(22):
2863 - 2864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Dhar, G S Pressman, S Subramanian, S Kaul, S Gollamudi, E J Bloom, and V M Figueredo
Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence
Postgrad. Med. J.,
June 1, 2009;
85(1004):
299 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Vassalle and M. G. Andreassi
Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon?
Clin. Chem.,
May 1, 2009;
55(5):
878 - 887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gao, C.-L. Long, R.-H. Wang, and H. Wang
KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function
Cardiovasc Res,
April 9, 2009;
(2009)
cvp099v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bolliger, M. D. Seeberger, G. A. L. Lurati Buse, P. Christen, B. Rupinski, L. Gurke, and M. Filipovic
A Preliminary Report on the Prognostic Significance of Preoperative Brain Natriuretic Peptide and Postoperative Cardiac Troponin in Patients Undergoing Major Vascular Surgery
Anesth. Analg.,
April 1, 2009;
108(4):
1069 - 1075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bernus, B. D. Wagner, F. Accurso, A. Doran, H. Kaess, and D. D. Ivy
Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension
Chest,
March 1, 2009;
135(3):
745 - 751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Semenov, A. B. Postnikov, N. N. Tamm, K. R. Seferian, N. S. Karpova, M. N. Bloshchitsyna, E. V. Koshkina, M. I. Krasnoselsky, D. V. Serebryanaya, and A. G. Katrukha
Processing of Pro-Brain Natriuretic Peptide Is Suppressed by O-Glycosylation in the Region Close to the Cleavage Site
Clin. Chem.,
March 1, 2009;
55(3):
489 - 498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Troughton and A. M. Richards
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kruger, S. Kotter, A. Grutzner, P. Lang, C. Andresen, M. M. Redfield, E. Butt, C. G. dos Remedios, and W. A. Linke
Protein Kinase G Modulates Human Myocardial Passive Stiffness by Phosphorylation of the Titin Springs
Circ. Res.,
January 2, 2009;
104(1):
87 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Andreassen, I. Raymond, C. Kistorp, P. Hildebrandt, J. Faber, and L. O. Kristensen
IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population
Eur. J. Endocrinol.,
January 1, 2009;
160(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Senggunprai, K. Yoshinari, M. Shimada, and Y. Yamazoe
Involvement of ST1B Subfamily of Cytosolic Sulfotransferase in Kynurenine Metabolism to Form Natriuretic Xanthurenic Acid Sulfate
J. Pharmacol. Exp. Ther.,
December 1, 2008;
327(3):
789 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vila, M. Resl, D. Stelzeneder, J. Struck, C. Maier, M. Riedl, M. Hulsmann, R. Pacher, A. Luger, and M. Clodi
Plasma NT-proBNP increases in response to LPS administration in healthy men
J Appl Physiol,
December 1, 2008;
105(6):
1741 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tagore, L. H. Ling, H. Yang, H.-Y. Daw, Y.-H. Chan, and S. K. Sethi
Natriuretic Peptides in Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol.,
November 1, 2008;
3(6):
1644 - 1651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lippi, G. Targher, and S. Z. Goldhaber
Natriuretic Peptides for Assessing the Prognosis of Acute Pulmonary Embolism
Chest,
June 1, 2008;
133(6):
1531 - 1532.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med.,
May 15, 2008;
358(20):
2148 - 2159.
[Full Text]
[PDF]
|
|
|
|
